Downloading...
Download

Bristol-myers

Bristol Myers Posts Q1 Loss, Revenue Rises 5% Stock Dives 8.35%Bristol Myers Squibb (NYSE: NYSE:BMY ) finds itself at a crossroads as it grapples with disappointing quarterly results and the announcement of significant workforce reductions. The pharmaceutical giant reported a first-quarter loss driven by charges related to recent acquisitions, sending its stock tumbling by 8%. Quarterly Performance: Bristol Myers' first-quarter loss, attributed to charges associated with acquisitions including Karuna Therapeutics, RayzeBio, and Mirati Therapeutics, amounted to $4.40 per share. While analysts had anticipated a loss of $4.41 per share, the company's net loss reached $5.89 per share. Despite the loss, revenue rose by 5% to $11.87 billion, surpassing analyst estimates of $11.48 billion. Strategic Restructuring: In a bid to streamline operations and save costs, Bristol Myers ( NYSE:BMY ) announced plans to slash its workforce by 6%, affecting approximately 2,200 employees. The restructuring aims to generate $1.5 billion in savings by the end of next year. CEO Christopher Boerner emphasized the company's commitment to long-term growth despite near-term challenges posed by patent expirations and pricing pressures. Challenges and Opportunities: Bristol Myers ( NYSE:BMY ) faces headwinds from impending patent expirations for key drugs like Eliquis and Opdivo, compounded by pricing negotiations and generic competition. To offset these losses, the company has pursued strategic acquisitions to bolster its pipeline and expand its portfolio. However, disappointing sales of certain products, including Camzyos and Sotyktu, underscore the urgency of driving innovation and diversification. Financial Outlook: The company revised its adjusted profit forecast for 2024 dramatically, now expecting earnings between 40 cents and 70 cents per share compared to the previous guidance of $7.10 to $7.40 per share. Despite the downward revision, analysts remain optimistic about Bristol Myers' ability to rebound, with full-year earnings estimates hovering around 66 cents per share. Investor Response: The announcement of workforce reductions and the revised earnings forecast sent shockwaves through the market, causing Bristol Myers' shares to plummet by nearly 8%. The market capitalization took a hit, shedding approximately $7 billion as investors digested the implications of the company's restructuring efforts amidst challenging market conditions.
NYSE:BMY
by DEXWireNews
BMY in a bearish flag continuation pattern.Bristol-Myers Squibb Co - 30d expiry - We look to Sell a break of 65.18 (stop at 67.68) Daily signals are bearish. There is no clear indication that the downward move is coming to an end. 65.95 has been pivotal. A break of the recent low at 65.28 should result in a further move lower. Price action is forming a bearish flag which has a bias to break to the downside. Our profit targets will be 59.18 and 58.18 Resistance: 68.00 / 70.00 / 72.00 Support: 65.28 / 63.00 / 60.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:BMYShort
by VantageMarkets
BMY: Always bet on pharma!Bristol-Myers Squibb Co Short Term - We look to Buy a break of 72.34 (stop at 70.99) Price action has formed a bullish ascending triangle formation. This is positive for sentiment and the uptrend has potential to return. Neckline resistance 72.00. A break of the neckline is required to confirm the formation. Further upside is expected. Our profit targets will be 75.96 and 80.00 Resistance: 72.00 / 80.00 / 100.00 Support: 71.00 / 65.00 / 60.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’) . Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:BMYLong
by VantageMarkets
$BMY to the mid-low $60s?$BMY has held up remarkably well during the market sell off. That said, I don't think that it's going to escape the downside for that much longer. We've tested the $77-78 region multiple times and just rejected again. Seeing the price action today makes me think that it's finally time for BMY to fall lower. Once $BMY breaks $75, there's not much holding it up. I think we could see a fairly quick move down to the $60 range, at $65 which would be the first support and $61 which would be the second support. There's a chance it falls into the $50s but I'll likely take profits in the $60s as it's rare for BMY to have such a substantial drop. Let's see what happens over the coming days/weeks.
NYSE:BMYShort
by benjihyam
2
BMY going South with a breeze. BMYImmediate targets 61, 59, 56, 53. Invalidation at 79. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:BMYShort
by Rykin_Capital
1
BMY Long Trade Idea Enter Long - Ideal price is $64-$66 Stop Loss - $64.4 Profit Target - $70-$71 ARK fund is dumping Bristol-Myers Squibb (BMY), should you? Yet another solid company with solid financials who is currently trading at 65.6% below estimated fair values. Earnings are forecasted to grow 30.88% per year. This stock also pays out a reliable dividend of 2.96%. Caution as there has been significant insider selling over the past 3 months. I plan on buying this at open tomorrow and holding for a few weeks or until price target is reached.  For the six months ended 30 June 2021, Bristol-Myers Squibb Co revenues increased 9% to $22.78B. Net income totaled $3.08B vs. loss of $860M. Revenues reflect Prioritized Brands-Eliquis segment increase of 18% to$5.68B, Prioritized Brands-Revlimid segment increase of 6%to $6.15B, United States segment increase of 9% to $14.4B,Europe segment increase of 11% to $5.24B.
NYSE:BMYLong
by DocKaz
BMY Flirting With Historic TerritoryWhen I say "historic" for BMY I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in mind for BMY longs. " Both Bristol-Myers and Novartis recently gave updates on new FDA updates. Novartis’ NIS793 gained FDA Orphan Drug Designation, while Bristol-Myers’ recent earnings update revealed strong sales figures from its lead cancer drug, Opdivo...B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment. While things are still in the very early stages for B7 molecules, as a whole, early research is also finding new potential for targeted cancer treatments. For instance, Merck’s (NYSE: MRK ) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment ." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NYSE:BMY
by PennyStocks101
CVS PHARMACY IS FILLING SCRIPTS FOR PALFORZIA - STRONG BUYWe just checked pharmacies around the North East PALFORZIA peanut allergy drug is available at CVS Pharmacy and is being filled at CVS Pharmacy CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations with over 9,600 pharmacies throughout the United States. Its parent company ranks as the 7th largest U.S. corporation by FY2017 revenues in the Fortune 500. The parent company of CVS Pharmacy's leading competitor (Walgreens) ranked 19th for the same time period. The stupid brokerage firms that just downgraded the stock price today because of a "so called slow roll-out" have no clue what they're doing or saying anymore. All these analysts had to do is pickup the phone and call around like we did! They're lazy!!! ANyone on this board wondering how easy it is to find out, call a CVS Pharmacy and ask them if they can fill a script for PALFORZIA, they will tell you YES,,, it is in the database for them to order..!!! We are passing along our research to some major brokerage firms so they will get behind the stock and push it up Palforzia Peanut Allergy Drug is available at CVS Pharmacy and soon to be available at Walgreens and other pharmacies throughout the USA This stock could blast off any day folks! We do not buy drug stocks so we are sitting on the sidelines just passing along solid and reliable information Factual information for this board is always a good thing to post especially since you don't get it from dumb analysts! DISCLAIMER This website and our posts are for general information only. No information, forward looking statements, or estimations presented herein represent any final determination on investment performance. While the information presented in this website and our posts has been researched and is thought to be reasonable and accurate, any investment is speculative in nature. StockKid, and/or our agents cannot and do not guarantee any rate of return or investment timeline based on the information presented herein. By reading and reviewing the information contained in this website and our posts, the user acknowledges and agrees that StockKid, and/or our agents do not assume and hereby disclaim any liability to any party for any loss or damage caused by the use of the information contained herein, or errors or omissions in the information contained in this website or our posts, to make any investment decision, whether such errors or omissions result from negligence, accident or any other cause. Investors are required to conduct their own investigations, analysis, due diligence, draw their own conclusions, and make their own decisions. Any areas concerning taxes or specific legal or technical questions should be referred to lawyers, accountants, consultants, brokers, or other professionals licensed, qualified or authorized to render such advice. In no event shall StockKid, and/or our agents be liable to any party for any direct, indirect, special, incidental, or consequential damages of any kind whatsoever arising out of the use of this website, our posts or any information contained herein. StockKid, and/or our agents specifically disclaim any guarantees, including, but not limited to, stated or implied potential profits, rates of return, or investment timelines discussed or referred to herein.
ALong
by UnknownUnicorn3159981
BMY Is starting a bull moveHey everyone, Another biomed related post today by request. BMY has double-bottomed as bulls grab a little control today on price. The stock has respected the BBands and is looking to move to the neutral region. The RSI teased in the oversold area, and price has responded with one of the two strong bull movements in the past four weeks as far as price movement goes. Price will struggle to break the $48.31 resistance that the massive bull volume failed to break on the 29th. We want to look for increasing bull volume as price recovers after hitting a low. If bull volume recovers with the next successive days, look at the $48.31 target for the first movement, with the $54 mark if price breaks through for the second movement. If bear volume trends or increasing in the next few days below the 45.15 support, the stock could break lower forming new lows for the year. Keep a tight stop loss in the meantime at the lower $45.15 support and long for the 48.31 and eventually the 54.44 if price starts to trend up with volume or if it ventures beyond the restraints of the BBands. -Block
NYSE:BMYLong
by block21e8
Short-Term Drop For BMY?On April 13, 2017, the Bristol-Myers Squibb ( BMY ) 20 day moving average (DMA) crossed below the 50 and 150 DMA. Both events have never occurred before on the same day. Historically 20 has crossed below the 50 DMA 129 times, and the 20 has crossed below the 150 DMA 53 times. For all of these instances, the stock does not always drop over the following 13 trading days. The cross below the 50 has a median loss of 3.056% and a maximum loss of 24.308% while the cross below the 150 has a median loss of 4.490% and a maximum loss of 35.795%. When we take a look at other technical indicators, the relative strength index (RSI) is at 32.6329. RSI tends to determine trends, overbought and oversold levels as well as likelihood of price swings. I personally use anything above 75 as overbought and anything under 25 as oversold. The current reading declares the stock is moving down. The true strength index (TSI) is currently -10.3049. The TSI determines overbought/oversold levels and/or current trend. I solely use this as an indicator of trend as overbought and oversold levels vary. The TSI is double smoothed in its calculation and is a great indicator of upward and downward movement. The current reading declares the stock is moving down. The positive vortex indicator (VI) is at 0.7249 while the negative is at 1.2883. When the positive level is higher than 1 and higher than the negative indicator, the overall price action is moving upward. When the negative level is higher than 1 and higher than the positive indicator, the overall price action is moving downward. The current reading declares the stock is still moving downward. The stochastic oscillator K value is 14.0765 and D value is 16.5090. This is a cyclical oscillator that is highly accurate and can be used to identify overbought/oversold levels as well as pending reversals and short-term activity. I personally use anything above 80 as overbought and below 20 as oversold. When the K value is higher than the D value, the price action is trending up. When the D value is higher that the K value, price action is trending down. The current reading declares the stock is stuck in oversold territory and it has been since March 24. This indicates the stock should move up soon or price action will decrease. Considering the moving average crossover, RSI, TSI, VI and stochastic levels, the overall direction appears to continue heading down. Based on historical movement compared to current levels and the current position, the stock could drop another 5% over the next 13 trading days.
NYSE:BMYShort
by StockSignaler